Company profilePharmaceutical#250 of 1,318 in Pakistan✓ No DRAP alerts

WNS FIELD PHARMACEUTICALS

Pharmaceutical company · 72 brands · 68 molecules

Ranked #16 of 62 companies in Antivirals For Systemic Use

72 registered products 27 pharmaceutical brands 68 distinct molecules 0 DRAP alerts

Company overview

72
registered products
27
pharmaceutical brands
68
distinct molecules
12
therapeutic classes
0
DRAP alerts

WNS FIELD PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 72 product registrations across 68 distinct molecules. Its portfolio is concentrated in Antivirals For Systemic Use and Other Beta-Lactam, Cephalosporins & Penems. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by WNS

4 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antiemetics & Antinauseants 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
Longest without revision

Top molecules by brand count

Ceftriaxone5 brands
Gabapentin2 brands
Cefixime2 brands
Folic Acid2 brands
Iron Salts2 brands
Lumefantrine2 brands
Artemether2 brands
Diclofenac2 brands
Omeprazole2 brands
Losartan2 brands

Therapeutic classes

Antivirals For Systemic Use · 4Other Beta-Lactam, Cephalosporins & Penems · 4Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 3Antihistamines For Systemic Use · 2Antiinflammatory And Antirheumatic Products · 2Gonadotropins And Other Ovulation Stimulants · 1Antidepressants · 1Antihaemorrhagic · 1Angiotensin-Ii Antagonists, Combinations · 1Antiemetics & Antinauseants · 1Quinolone Antibacterials · 1Pain Management · 1

Conditions treated

Pain Killers · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO2 products · Rs 73.15 – Rs 301.15
Servaid1 products · Rs 579 – Rs 579
Median across source: Rs 579

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 132 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin
SHROOQ PHARMACEUTICALS holds 21 molecules not in this portfolio
AcitretinAcyclovirAcyclovir Inf/OralCefiximeCiprofloxacinDiclofenac
Horizon Pharmaceuticals (Pvt) Limited holds 137 molecules not in this portfolio
000 I.UAcyclovirAlbendazoleAmlodipineAmoxicillinAmoxycillin Base

Get the full profile for WNS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.